Citius Pharmaceuticals, Inc.
CTXR
$0.56
-$0.03-5.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -94.49% | 15.84% | 26.24% | 16.87% | -27.77% |
| Total Depreciation and Amortization | 3,044.64% | 916.42% | 15.46% | -21.59% | 7.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -240.07% | 55.86% | -4.09% | -22.49% | -28.59% |
| Change in Net Operating Assets | 444.13% | -427.96% | -374.34% | 166.40% | 251.07% |
| Cash from Operations | 71.36% | -175.27% | -100.94% | 35.38% | 41.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -15.00% | -- | -- |
| Cash from Investing | -- | -- | -15.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 711.08% | 18,546.99% | -23.69% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -135.52% | 711.08% | 521.56% | -16.40% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -191.63% | 261.22% | 87.47% | 13.29% | 86.21% |